The Effects of Nateglinide and Acarbose on the Post-Prandial Glucose Control in Type 2 Diabetic Patients

This study has been completed.
Sponsor:
Collaborator:
Sanofi
Information provided by:
Inje University
ClinicalTrials.gov Identifier:
NCT00437918
First received: February 20, 2007
Last updated: March 21, 2008
Last verified: March 2008
  Purpose

In type 2 diabetic patients, tight blood glucose control often requires both fasting and post-prandial glucose control separately. In the diabetic patients already on the insulin glargine treatment for the control of fasting blood glucose, additional measures for the control of post-prandial glucose level are often required. Nateglinide and acarbose are frequently used for this purpose. We hypothesized that the short acting sulfonylurea "nateglinide" may be more efficacious in diabetic patients with appreciable endogenous insulin secretion, while acarbose may be more efficacious in patients with lower endogenous insulin secretion. And we also want to clarify the clinical and biochemical parameters that can predict the responsiveness to each agent in this multi-center randomized open cross-over clinical study.


Condition Intervention Phase
Diabetes Mellitus
Type 2 Diabetes Mellitus
Drug: nateglinide
Drug: acarbose
Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Crossover Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Phase IV Study on Predictive Markers for the Effectiveness of Nateglinide or Acarbose for Controlling Post-Prandial Glucose in Type 2 Diabetics Already on Optimized Insulin Glargine Therapy

Resource links provided by NLM:


Further study details as provided by Inje University:

Primary Outcome Measures:
  • 7 point SMBG (self monitoring of blood glucose) [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • HOMA-beta for predicting the effectiveness of each agents [ Designated as safety issue: No ]

Enrollment: 85
Study Start Date: January 2007
Study Completion Date: March 2008
Primary Completion Date: March 2008 (Final data collection date for primary outcome measure)
  Eligibility

Ages Eligible for Study:   40 Years to 80 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Korean
  • Type 2 diabetes mellitus
  • No prior history of diabetic ketoacidosis
  • HbA1c between 7.5-10.0%

Exclusion Criteria:

  • Type 1 diabetes mellitus
  • Gestational diabetes mellitus
  • Secondary diabetes mellitus
  • Severe hyperglycemia with symptoms
  • Severe chronic diabetic complications (PDR,s-Cr>1.3mg/dL)
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00437918

Locations
Korea, Republic of
Paik Diabetes Center, Pusan Paik Hospital, College of Medicine, Inje University
Busan, Korea, Republic of, 614-735
Endocrinology and Metabolism, Maryknoll General Hospital
Busan, Korea, Republic of
Sponsors and Collaborators
Inje University
Sanofi
Investigators
Principal Investigator: Jeonghyun Park, MD PhD Director, Paik Diabetes Center, Pusan Paik Hospital, College of Medicine, Inje University
  More Information

No publications provided by Inje University

Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: Jeong Hyun Park, MD PhD / Professor, Inje University Pusan Paik Hospital / Paik Diabetes Center
ClinicalTrials.gov Identifier: NCT00437918     History of Changes
Other Study ID Numbers: PDC-07-01
Study First Received: February 20, 2007
Last Updated: March 21, 2008
Health Authority: Korea: Food and Drug Administration

Additional relevant MeSH terms:
Diabetes Mellitus
Diabetes Mellitus, Type 2
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases
Acarbose
Nateglinide
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Hypoglycemic Agents
Physiological Effects of Drugs

ClinicalTrials.gov processed this record on July 26, 2014